logo
Why Wall Street kept sending the S&P 500, Nasdaq to fresh records this week

Why Wall Street kept sending the S&P 500, Nasdaq to fresh records this week

CNBCa day ago
The stock market ended the week higher as Wall Street speculated on how a spate of economic releases would impact the Federal Reserve's next interest rate decision. The S & P 500 and Nasdaq both gained nearly 1% over the past five sessions. Both benchmark gauges hit several record closes this week, with the S & P 500 reaching the milestone on Tuesday, Wednesday, and Thursday. The tech-heavy Nasdaq closed at record highs on Tuesday and Wednesday. Both indexes hit all-time intraday highs on Friday but closed the session modestly lower. Inflation data Stocks were pushed much higher on Tuesday, which carried the week, after the July consumer price index showed inflation had cooled more than expected. This caused Fed rate cut expectations for September to rise. The stock market's run continued into Wednesday's session. On Thursday, however, stocks lost some momentum after July's producer price index indicated that wholesale inflation rose more than expected last month. Despite higher inflation figures, though, the market odds of a rate cut at the Fed's meeting next month didn't decrease by much, according to the CME FedWatch tool. A second Fed rate cut by the end of the year is also expected. Cisco's quarter Our focus was also on quarterly earnings Wednesday evening from Cisco Systems , the latest addition to the Club's portfolio. Cisco beat analysts' expectations for the top and bottom lines during its fiscal 2025 fourth quarter. The company experienced strong revenue growth within its networking business thanks to the boom in AI infrastructure spending. Orders within the networking business surpassed $800 million during the fiscal fourth quarter, bringing the total to more than $2 billion for fiscal 2025. That's double management's goal for the year. Still, shares slipped after the release due to the significant revenue miss in Cisco's security division. That didn't shake our conviction in the stock, though. The Club reiterated our buy equivalent 1 rating , and maintained our price target of $78. "In a market that rewards AI-exposed companies with lofty valuations, Cisco trades at a very reasonable high teens price-to-earnings multiple. That valuation is too cheap to us," Jeff Marks, director of portfolio analysis for the Club, wrote in his earnings analysis. Later in the week, commentary from one Wall Street firm sent Cisco stock lower again. Shares fell 5.5% on Friday after HSBC downgraded the stock to a hold rating from a buy, and lowered its price target to $69 from $73. Analysts viewed Cisco's quarterly report as lackluster and said more stock gains would be hard to come by. "Though the company reported more than USD2bn of AI infrastructure orders in FY25, strength seems to be getting offset by weakness elsewhere," HSBC wrote in a Thursday note to clients. Record highs Although Cisco stock had a tough week, many other portfolio names experienced big runs. In fact, five Club holdings reached record highs since Monday. In no particular order, here's a breakdown of each. Goldman Sachs briefly reached an all-time high Friday of $749.05. But shares then tumbled 2.2% into the close. BlackRock hit a record Wednesday of $1,171.89. The stock drifted lower to around $1,135 by Friday's close. Broadcom on Wednesday touched $317.35, its highest stock price ever. Nvidia shares jumped to a record of $184.48 on Tuesday. Meta Platforms stock climbed to an all-time high of $796.25 on Friday. Portfolio moves We executed three trades last week, including exiting one position entirely. First, we bought more shares of Starbucks and Palo Alto Networks on Monday after unreasonable sell-offs. On Thursday, we sold the rest of our small Coterra Energy position. It no longer made sense to invest in Coterra in the current economic environment. Jim Cramer talked about this at length during the Club's August Monthly Meeting. We didn't just buy and sell, though. The Club changed ratings on two portfolio names as well. A new piece of Wall Street research led us to downgrade Salesforce on Monday to a hold-equivalent 2 rating. Analysts at Melius Research came out with a note that outlined the headwinds that generative AI could have on software-as-a-service companies like Salesforce. Shares then popped nearly 4% on Friday after filings revealed that Jeff Smith's Starboard Value increased its stake in Salesforce by 47% during the second quarter. That renewed bets that activists will push for change again, as they did with success a couple of years ago. After two terrible weeks, the stock finished this week up almost 1%. Two sessions later, the Club double upgraded Eli Lilly shares to a buy-equivalent 1 rating after CEO David Ricks and other company insiders bought a significant amount of the slumping stock. Health-care stocks, which had been struggling as a sector, have gotten a boost over the past week or so. Lilly stock was our best performer this week, jumping 12%. (See here for a full list of the stocks in Jim Cramer's Charitable Trust.) As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust's portfolio. If Jim has talked about a stock on CNBC TV, he waits 72 hours after issuing the trade alert before executing the trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB. NO SPECIFIC OUTCOME OR PROFIT IS GUARANTEED.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

PMTS Investors Have Opportunity to Join CPI Card Group Inc. Fraud Investigation with the Schall Law Firm
PMTS Investors Have Opportunity to Join CPI Card Group Inc. Fraud Investigation with the Schall Law Firm

Business Wire

time3 minutes ago

  • Business Wire

PMTS Investors Have Opportunity to Join CPI Card Group Inc. Fraud Investigation with the Schall Law Firm

LOS ANGELES--(BUSINESS WIRE)-- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of CPI Card Group Inc. ('CPI' or 'the Company') (NASDAQ: PMTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. CPI announced its Q2 2025 financial results on August 8, 2025. The Company missed analyst estimates for both revenue and earnings per share. The Company also updated its 2025 outlook based on the acquisition of Arroweye Solutions in May 2025. Based on this news, shares of CPI fell by more than 28.8% on the same day. If you are a shareholder who suffered a loss, click here to participate. We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at or by email at bschall@ The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

2 Top Dividend Stocks Duke It Out. Which Is Better?
2 Top Dividend Stocks Duke It Out. Which Is Better?

Yahoo

time2 hours ago

  • Yahoo

2 Top Dividend Stocks Duke It Out. Which Is Better?

Key Points On top of its regular dividend, Costco also occasionally pays out a much bigger special dividend. Both companies increased their dividend this year. Valuation is ultimately what makes one stock a better buy than the other. 10 stocks we like better than Alphabet › When investors think about dividend stocks, they usually start with high-yielding names. Utilities, telecoms, and big consumer staples often dominate the conversation. But sometimes the best dividend opportunities come from companies with low payouts. That's where membership-based wholesale retailer Costco (NASDAQ: COST) and Google parent Alphabet (NASDAQ: GOOG)(NASDAQ: GOOGL) come in. Both yield less than 1%, making them easy to dismiss for income. Yet, both are outstanding businesses with excellent dividend growth prospects. Costco, specifically, delivers incredible stability and even pays occasional special dividends on top of its regular dividend. Meanwhile, Alphabet has a brand-new payout and is one of the cheapest valuations among big tech. But which one of these two dividend growth stocks edges out the other when compared head-to-head? Costco: Dependable income at a high price Costco has a reputation for consistency, and its dividend reflects that. The company's payout is below 30%, leaving plenty of room for business reinvestment and steady dividend increases over time. Additionally, Costco has increased its dividend every year for more than two decades, with an annual growth rate of around 13% in recent years. The latest raise came this spring, when management boosted the quarterly dividend to $1.30. That puts the annual payout at $5.20 and the dividend yield at roughly 0.5%. Notably, Costco offers more than just its regular dividend. From time to time, the company pays special dividends, too. In early 2024, for instance, shareholders received a $15 special dividend. These extra payouts can make a big difference for long-term holders, even though they come only occasionally. The issue with Costco, however, is the stock's valuation. Shares trade at more than 50 times earnings, a very high multiple for a stock that grew its sales and earnings per share 8% and 13%, respectively, in its most recent quarter. That premium reflects both the quality of the business and investors' willingness to pay up for its reliability. But such a lofty valuation leaves little margin for error. Even though sales and earnings continue to grow at a healthy pace, today's stock price already bakes in years of strong performance. Investors buying now should expect modest returns from here unless Costco delivers upside surprises. Alphabet: Small yield, big upside Alphabet only started paying a dividend in 2024, so it doesn't have Costco's long track record. The payout is small, with an annual dividend of $0.84 per share and a yield of around 0.4%. But the payout ratio is less than 10%. That leaves huge room for growth if management decides to raise the dividend in future years. The company is also aggressively investing in its business (perhaps explaining why management increased its dividend by only 5% this year). Capital expenditures are surging as Alphabet builds out its artificial intelligence (AI) and cloud infrastructure. Sure, this has weighed on free cash flow in the short term. But investors should remember that these investments are aimed at capturing long-term growth opportunities. Making the case for Alphabet stock even stronger, the internet search and cloud computing company's growth story benefits from a diversified set of key revenue sources -- and they're all doing well. Alphabet's advertising business remains strong, YouTube continues to expand, and Google Cloud is gaining ground. Unlike Costco, valuation is a bright spot for Alphabet. Shares trade at about 21 times forward earnings -- a much lower multiple than tech peers like Microsoft and Meta and far below Costco. That's unusual for a company still posting strong double-digit growth in both revenue and profits. Revenue and operating income both increased 14% year over year in the company's second quarter of 2025. With earnings growth like this, Alphabet could ramp up its dividend in a big way down the road (though it might have to get through a period of high capital expenditures first as it invests aggressively in growth). A clear winner Costco and Alphabet may both look like low-yield stocks, but they represent two very different kinds of dividend investments. Costco is the steady option. It offers a safe payout, regular increases, and the occasional special dividend. But investors pay a steep price for that safety, which limits future returns. Alphabet, by contrast, has only just begun rewarding shareholders with dividends. The yield is tiny but could grow substantially over time. More importantly, the tech stock's valuation is much cheaper than Costco's. For investors willing to accept a small payout today in exchange for better long-term potential, Alphabet is the clear winner. Should you invest $1,000 in Alphabet right now? Before you buy stock in Alphabet, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Alphabet wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,155!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,106,071!* Now, it's worth noting Stock Advisor's total average return is 1,070% — a market-crushing outperformance compared to 184% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 13, 2025 Daniel Sparks and his clients do not have positions in any of the stocks mentioned. The Motley Fool has positions in and recommends Alphabet, Costco Wholesale, Meta Platforms, and Microsoft. The Motley Fool recommends the following options: long January 2026 $395 calls on Microsoft and short January 2026 $405 calls on Microsoft. The Motley Fool has a disclosure policy. 2 Top Dividend Stocks Duke It Out. Which Is Better? was originally published by The Motley Fool

1 Beaten-Down Stock That Could Soar by the End of the Year
1 Beaten-Down Stock That Could Soar by the End of the Year

Yahoo

time2 hours ago

  • Yahoo

1 Beaten-Down Stock That Could Soar by the End of the Year

Key Points Viking's leading weight management candidate is being investigated in two formulations. The stock could soar later this year, provided the oral version aces phase 2 studies. Viking Therapeutics is somewhat risky, but it also has significant upside potential. 10 stocks we like better than Viking Therapeutics › Some smaller drugmakers choose to develop medicines for diseases for which there are no therapeutic options. This allows them to avoid direct competition from larger pharmaceutical companies. That's not exactly the strategy Viking Therapeutics (NASDAQ: VKTX) chose. The mid-cap biotech is working on weight loss therapies, an increasingly competitive market dominated by Eli Lilly (NYSE: LLY) and Novo Nordisk, as well as numerous other well-established players in the industry seeking to enter the space. Going up against these giants is no small challenge, but Viking is, so far, holding its own. And if it can play its cards right, its stock could soar by the end of the year and go on to generate strong returns from then on out. Here's more on Viking Therapeutics. Eli Lilly's setback creates an opportunity Viking Therapeutics' shares soared last year following the release of strong phase 2 data for its subcutaneous weight management candidate, VK2735. The stock has declined significantly since that milestone, although it's not due to anything Viking did wrong. Broader market volatility, combined with long-term shareholders taking some profits, is likely responsible for the stock's 40% drop over the trailing-12-month period. VK2735 is currently in phase 3 studies, but Viking is also developing an oral version of the medicine, which is in phase 2 clinical trials. There is a race to develop a highly effective oral GLP-1 anti-obesity therapy, since the current market leaders are administered via subcutaneous injection. If Viking Therapeutics' oral candidate can impress in mid-stage studies, the stock could soar. That's especially the case since Eli Lilly's investigational oral GLP-1 medicine, orforglipron, failed to perform as well as expected in a phase 3 study in obese or overweight patients who didn't have diabetes. Orforglipron led to a mean weight loss of 12.4% in a 72-week study, which wasn't as impressive as the market wanted. This result paled in comparison to Lilly's injectable Zepbound, which led to an average weight loss of 20.2% in a phase 3 study. Viking Therapeutics' shares jumped on the pharmaceutical giant's bad news, but there's plenty of upside left if its oral weight loss candidate meets Wall Street's expectations. It's best to start small Eli Lilly is perceived as the leader in the weight management market. The company's continued dominance in this field was likely somewhat baked into investor expectations, requiring it to deliver outstanding clinical trial results to justify its share price. Viking is a much smaller drugmaker than Lilly, so the market will likely have lower expectations for its data readouts for VK2735. Viking also has several other exciting candidates. The company is working on a drug called VK2809, a potential therapy for metabolic dysfunction-associated steatohepatitis (MASH), which produced solid results in phase 2 studies. There is a vast unmet need in MASH, considering several million people have the disease, yet the U.S. Food and Drug Administration has approved just a single medication for it. Elsewhere, Viking has a next-gen anti-obesity candidate that could soon start human clinical trials. The company has a lot going on, and if VK2735-related developments remain strong through the end of the year, the stock could soar. However, Viking -- like any clinical-stage biotech company -- is a somewhat risky bet. On the one hand, it has generated strong mid-stage data for two separate medicines that address high unmet needs. Its leading candidate, VK2735, has the potential to become a blockbuster; that's impressive. Even so, the stock will plummet if VK2735 encounters clinical setbacks. So, should you buy shares? In my view, it depends on your level of risk tolerance. Risk-averse investors should look elsewhere. If you're comfortable with a bit of volatility, you should seriously consider the stock; however, it would be wise to start by initiating a small position. If the data from the ongoing phase 2 study for oral VK2735 is good, it might be worth adding even more shares thereafter. Should you buy stock in Viking Therapeutics right now? Before you buy stock in Viking Therapeutics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Viking Therapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,155!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,106,071!* Now, it's worth noting Stock Advisor's total average return is 1,070% — a market-crushing outperformance compared to 184% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 13, 2025 Prosper Junior Bakiny has positions in Eli Lilly, Novo Nordisk, and Viking Therapeutics. The Motley Fool recommends Novo Nordisk and Viking Therapeutics. The Motley Fool has a disclosure policy. 1 Beaten-Down Stock That Could Soar by the End of the Year was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store